✨ Medicines Consent Notices
2732 NEW ZEALAND GAZETTE No. 114
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Novartis Pharmaceuticals Corporation, New York, U.S.A.
Note: This consent is valid for 2 years from the 7th day of September 1999.
Product: Exelon.
Active Ingredient(s): Rivastigmine (as hydrogen tartrate) 0.8 mg equivalent to 0.5 mg rivastigmine.
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Note: This consent is valid for 2 years from 13th day of November 1999.
Product: Exelon.
Active Ingredient(s): Rivastigmine (as hydrogen tartrate) 1.6 mg equivalent to 1 mg rivastigmine.
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Note: This consent is valid for 2 years from 13th day of November 1999.
Product: Exelon.
Active Ingredient(s): Rivastigmine (as hydrogen tartrate) 2.4 mg equivalent to 1.5 mg rivastigmine.
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Note: This consent is valid for 2 years from 13th day of November 1999.
Product: Exelon.
Active Ingredient(s): Rivastigmine (as hydrogen tartrate) 4.8 mg equivalent to 3 mg rivastigmine.
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Note: This consent is valid for 2 years from 13th day of November 1999.
Product: Exelon.
Active Ingredient(s): Rivastigmine (as hydrogen tartrate) 7.2 mg equivalent to 4.5 mg rivastigmine.
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Note: This consent is valid for 2 years from 13th day of November 1999.
Product: Exelon.
Active Ingredient(s): Rivastigmine (as hydrogen tartrate) 9.6 mg equivalent to 6 mg rivastigmine.
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Note: This consent is valid for 2 years from 13th day of November 1999.
Dated this 6th day of September 1999.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
g06614
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1999, No 114
NZLII —
NZ Gazette 1999, No 114
✨ LLM interpretation of page content
🏥
Renewal of Provisional Consent to the Distribution of a New Medicine
(continued from previous page)
🏥 Health & Social Welfare6 September 1999
Medicines, Distribution, Renewal, Actigall, Exelon, Rivastigmine, Capsule, Novartis
- G. R. Boyd, Chief Advisor, Safety and Regulation